boronophenylalanine
Commercial- Indications
- Head and neck cancer, Glioblastoma
Company intelligence / Profile preview
Neutron Therapeutics develops the nuBeam BNCT Suite, an investigational hospital-based accelerator system for Boron Neutron Capture Therapy. This targeted radiation modality aims to selectively destroy tumor cells while sparing healthy tissue. The system offers higher neutron flux than competitors and meets IAEA standards. Clinical results are pending regulatory approval; no commercial use yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Neutron Therapeutics.